Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
The present clinical trial will investigate the efficacy of a sequential interval-shortened
and dose-intensified preoperative use of epirubicin, paclitaxel and CMF with preoperative
sequential administration of epirubicin and cyclophosphamide followed by paclitaxel in breast
cancer. In addition, the influence of darbepoetin alfa on the response rate and quality of
life is to be investigated in both treatment arms.